Balance Sheet Data

Halozyme Therapeutics, Inc. (HALO)

$57.57

-0.17 (-0.29%)

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash 469.21354.53421.26368.01740.92957.331,146.931,374.081,646.231,972.27
Total Cash (%)
Account Receivables 22.1330.0159.4497.7390.98121.22145.23173.99208.45249.74
Account Receivables (%)
Inventories 5.1522.6329.3660.7553.9170.4984.46101.18121.22145.23
Inventories (%)
Accounts Payable 7.954.086.431.931.5410.1412.1514.5617.4420.89
Accounts Payable (%)
Capital Expenditure -1.35-4.66-4.04-2.50-1.46-7.25-8.68-10.40-12.46-14.93
Capital Expenditure (%)



To support growth, companies need to keep investing in capital items – including property, plants and equipment.
To calculate this net investment,we take capital expenditure (found in the company’s statement of cash flows) and subtract non-cash depreciation (found on the income statement).
Working capital refers to the cash a company needs for day-to-day operations.
The faster a company expands, the more cash it will need.
To calculate working capital, we take current assets and subtract current liabilities.
You can find both of these on a company’s balance sheet, which is published in its quarterly and annual financial statements.